BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
22 janv. 2019 07h30 HE
|
BioCorRx Inc
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Provides BICX102 Grant Update
02 oct. 2018 07h51 HE
|
BioCorRx Inc
ANAHEIM, CA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Provides Business Update for the First Quarter of 2018
21 mai 2018 07h30 HE
|
BioCorRx, Inc.
ANAHEIM, CA, May 21, 2018 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided...
BioCorRx Comments on President Donald J. Trump’s Initiative to Stop Opioid Abuse
20 mars 2018 10h40 HE
|
BioCorRx Inc
ANAHEIM, CA, March 20, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions,...
Dr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The Doctors
15 févr. 2018 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, Feb. 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
12 févr. 2018 09h23 HE
|
BioCorRx Inc
505(b)(2) application plan acceptable per FDA Application will seek dual indications for opioid and alcohol use disorders ANAHEIM, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- BioCorRx...
BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA
08 févr. 2018 07h30 HE
|
BioCorRx, Inc.
ANAHEIM, CA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Completes Pre-IND Meeting with FDA; Reports Company to Move Forward with BICX102
26 janv. 2018 07h30 HE
|
BioCorRx, Inc.
ANAHEIM, CA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...